Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2020 | Story Eugene Seegers | Photo Charl Devenish
Gugu believes in empowering students to successfully complete their higher-education journey.

Gugu Wendy Tiroyabone is Head of Advising, Access and Success in the Centre for Teaching and Learning. She says she is on a journey to become a champion womxn, with her advocacy for student access with success in higher education being the vehicle that is propelling her. Gugu says her superpower is “knowing how to win without being loud”.

1. Please tell us about yourself: Who are you and what do you do at the university? 
Self-awareness, simplicity, and service is who I am and what I, Gugu Wendy Tiroyabone (née Khanye), embody. My Zulu name, loosely translated, means ‘precious’, and I firmly believe that the work I do at the UFS Centre for Teaching and Learning — academic advising and RPL — align with my name, serving students in this invaluable experience of being afforded the opportunity to access higher education and ultimately being guided to success.

2. Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?
Mmm … tricky to single out only one. There are a few — top of the charts is most certainly my mother, a servant leader — in everything she does; she is there to listen, hear and understand, empathise, heal, build, and is committed to the growth of others. Aunty Basetsana (Bassie) Kumalo is another womxn I celebrate – television personality, businesswomxn, and philanthropist — a brand that inspires me to be the best version of me so that I can reach my dreams.

3. What are some of the challenges you’ve faced in your life that have made you a better woman?
I would say one of the biggest challenges I faced in my early 20s would have to be low self-confidence and a low self-esteem. Those who know me would disagree, but unfortunately it gets the best of us and it was my reality. I struggled with acceptance, and when I took some time out to check in with myself, I learned that knowing how to win without making a noise is my superpower; since realising this, I refuse to live below my potential.

4. What advice would you give to a 15-year-old you?
You don’t have to change your dreams to realise them; rather, as you grow, adapt and adopt your approaches to the season/year — these small adaptations will propel you towards fulfilling your dreams. Someone else can make your dreams come true, but only you can realise your dreams.

5. What would you say makes you a champion woman, or a champion woman of the UFS?
I would like to believe that I am still becoming a champion womxn, not there just yet. But my advocacy for student access with success in higher education is what is driving me towards being a champion womxn – without meaningful access, student success is hollow. So, we need to work collectively as a sector and institution to achieve this.

 

 

 

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept